Latest Report on Ophthalmology Therapeutics - Gene Therapies and First-in-Class Targets Offer Novel Treatments | Angiogenic and Immune Signaling Drugs

Researchmoz added Most up-to-date research on "Frontier Pharma: Ophthalmology Therapeutics - Gene Therapies and First-in-Class Targets Offer Novel Treatments for Substantial Unmet Needs in a Pipeline Dominated by Angiogenic and Immune Signaling Drugs" to its huge collection of research reports.

The ophthalmologic therapy area encompasses a wide range of disorders affecting the eye and its supporting structures. These include glaucoma, age-related macular degeneration (AMD), diabetic retinopathy (DR), diabetic macular edema (DME) and dry eye syndrome (DES). The therapy area is characterized by vast unmet need, as patients have few treatment options and poor outcomes.

This report assesses first-in-class innovation in the ophthalmology pipeline, highlighting key trends in the distribution of these products. In-depth analysis reveals that the level of innovation within the therapy area pipeline is high, with strong potential for drugs to address unmet needs and be commercially lucrative. First-in-class drugs account for 38% of products with a disclosed molecular target, acting on 151 unique molecular targets, which is indicative of the approach being taken in the field.

To Get Sample Copy of Report visit @ https://www.researchmoz.us/enquiry.php?type=S&repid=1370887

In the past the ophthalmological disorders therapy area has suffered from a lack of full understanding of the pathophysiology and underlying mechanisms of the diseases. However, as this knowledge has improved vastly in recent years, potential targets have been identified for treatment. As well as the main disorders previously mentioned, there is also interest in developing treatments for indications such as allergic conjunctivitis and retinitis pigmentosa. The approval of a gene therapy for retinitis pigmentosa is indicative of this progress, and represents the first gene therapy approved for an inherited condition by the FDA.

The pipeline is varied in terms of molecular targets and molecule types. Products acting on the immune system and neurotransmitter signaling are the most prevalent, but no single target dominates by any clear margin. There are a total of 194 first-in class pipeline products in development for ophthalmologic indications - 38% of the 512 pipeline products for which there is a disclosed molecular target. Encompassing gene therapies, slowing of the visual cycle and antisense therapies, the pipeline appears robust and has huge potential to strengthen treatment options for ophthalmological disorders.

Scope

- The pipeline is large, with 865 products in active development. Does current pipeline innovation hold the potential to affect the future ophthalmology market?
- There are 194 first-in-class products in the ophthalmologic disorder pipeline. Which of these possess the greatest potential to improve disease outcome and be commercially successful, based on their target?
- Analysis of strategic consolidations and deals revealed a high level of activity in recent years for licensing agreements, but a low level of co-development. How do deal frequency and value compare between molecular targets and molecule types, and which first-in-class targets have not yet been involved in deals?

Reasons to buy

- Understand the current clinical and commercial landscape. This includes a comprehensive study of disease pathogenesis, diagnosis and prognosis, and the treatment options available.
- Visualize the composition of the ophthalmological disorders market in terms of dominant molecule types and targets, and understand the current unmet needs and how they can be addressed. This knowledge allows a competitive understanding of gaps in the market.
- Analyze the ophthalmological disorders pipeline and stratify by stage of development, molecule type and molecular target. There are strong signs in the pipeline that the industry is seeking novel approaches to treating ophthalmological disorders to overcome the overwhelming level of unmet need.
- Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix, first-in-class products have been assessed and ranked according to clinical potential. Promising early-stage targets have been reviewed in greater detail.
- Identify commercial opportunities in the ophthalmological disorders deals landscape by analyzing trends in licensing and co-development deals, and a curated list of ophthalmological disorder therapies that have not yet been involved in deals, and may offer potential investment opportunities.

Get Complete TOC With Tables and Figures @ https://www.researchmoz.us/frontier-pharma-ophthalmology-therapeutics-gene-therapies-and-first-in-class-targets-offer-novel-treatments-for-substantial-unmet-needs-in-a-pipeline-dominated-by-angiogenic-and-immune-signaling-drugs-report.html/toc

Table of Contents

1 Table of Contents 21.1 List of Tables 3
1.2 List of Figures 3

2 Executive Summary 5
2.1 Market Landscape Poised for Entry of Novel Products 5
2.2 Moderately Sized but Strong First-in-Class Pipeline 5
2.3 Strong Uptake of First-in-Class Products in Strategic Consolidations 5

3 The Case for Innovation 6
3.1 Growing Opportunities for Biologic Products 7
3.2 Diversification of Molecular Targets 7
3.3 Innovative First-in-Class Product Development Remains Attractive 7
3.4 Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation 8
3.5 Sustained Innovation 8
3.6 GBI Research Report Guidance 9

4 Clinical and Commercial Landscape 10
4.1 Therapy Area Overview 10
4.1.1 Glaucoma 10
4.1.2 Age-related Macular Degeneration 10
4.1.3 Diabetic Macular Edema 10
4.1.4 Diabetic Retinopathy 10
4.1.5 Dry Eye Syndrome 11
4.1.6 Inherited Genetic Disorders 11
4.2 Disease Symptoms 11
4.3 Epidemiology and Etiology 12
4.3.1 Glaucoma 13
4.3.2 Age-Related Macular Degeneration 13
4.3.3 Diabetic Retinopathy and Diabetic Macular Edema 13
4.3.4 Dry Eye Syndrome 13
4.4 Diagnosis 13
4.5 Pathophysiology 14
4.5.1 Healthy Eye Physiology 14
4.5.2 Glaucoma 15
4.5.3 Age-Related Macular Degeneration 16
4.5.4 Diabetic Macular Edema and Diabetic Retinopathy 17
4.5.5 Dry Eye Syndrome 17
4.5.6 Inherited Genetic Diseases 18
4.6 Prognosis 18
4.6.1 Glaucoma 18
4.6.2 Age-Related Macular Degeneration 19
4.6.3 Diabetic Retinopathy and Diabetic Macular Edema 19
4.6.4 Dry Eye Syndrome 19
4.7 Treatment Options 20
4.8 Overview of Marketed Products in Ophthalmology 22
4.8.1 Molecule Type and Target Analysis 22

5 Assessment of Pipeline Product Innovation 23
5.1 Ophthalmology Pipeline by Molecular Target 26
5.2 Comparative Distribution of Programs between the Ophthalmology Market and Pipeline by Therapeutic Target Family 28
5.3 First-in-Class Pipeline Programs Targeting Novel Molecular Targets 29

6 Signaling Network, Disease Causation and Innovation Alignment 40
6.1 Complexity of Signaling Networks in Ophthalmology 40
6.2 Signaling Pathways and First-in-Class Molecular Target Integration 40
6.3 First-in-Class Matrix Assessment 41

Continue...

Make an Enquiry of this report @ https://www.researchmoz.us/enquiry.php?type=E&repid=1370887

About ResearchMoz

ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.

ResearchMoz
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Email: sales@researchmoz.us
Website @ https://www.researchmoz.us/
Tel: 866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-621-2074
Follow us on LinkedIn @ http://bit.ly/1TBmnVG

This release was published on openPR.